Scarlet Therapeutics

Bristol-based biotechnology company Scarlet Therapeutics has successfully secured £3.2 million in seed funding to advance its universal blood cell therapy.

Summary of transaction details:

• Value: £3.2 million
• Sector: Healthcare & Biotech
• Advisor: Not mentioned
• Key Entities: Target: Scarlet Therapeutics
• Location: Bristol, UK

Note: This funding round will enable Scarlet Therapeutics to further develop its proprietary lab-grown red blood cells, which are designed to be universally compatible, removing the need for blood-type matching in transfusions and addressing a broad patient demographic.